Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms

Drug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dtmax) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects ea...

Full description

Bibliographic Details
Main Authors: Brian D. Guth, Michael Engwall, Sandy Eldridge, C. Michael Foley, Liang Guo, Gary Gintant, John Koerner, Stanley T. Parish, Jennifer B. Pierson, Alexandre J. S. Ribeiro, Tanja Zabka, Khuram W. Chaudhary, Yasunari Kanda, Brian Berridge
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.00884/full
id doaj-e6b42e00ab1d407c9c50c66883fb0686
record_format Article
spelling doaj-e6b42e00ab1d407c9c50c66883fb06862020-11-24T20:53:12ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122019-08-011010.3389/fphar.2019.00884460082Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing PlatformsBrian D. Guth0Brian D. Guth1Michael Engwall2Sandy Eldridge3C. Michael Foley4Liang Guo5Gary Gintant6John Koerner7Stanley T. Parish8Jennifer B. Pierson9Alexandre J. S. Ribeiro10Tanja Zabka11Khuram W. Chaudhary12Yasunari Kanda13Brian Berridge14Department of Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, GermanyPreClinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South AfricaSafety Pharmacology and Animal Research Center, Amgen Research, Thousand Oaks, CA, United StatesDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, United StatesDepartment of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United StatesLaboratory of Investigative Toxicology, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, MD, United StatesDepartment of Integrative Pharmacology, Integrated Sciences and Technology, AbbVie, North Chicago, IL, United StatesCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United StatesHealth and Environmental Sciences Institute, Washington, DC, United StatesHealth and Environmental Sciences Institute, Washington, DC, United StatesDivision of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translation Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, United States0Department of Safety Assessment, Genentech, South San Francisco, CA, United States1Global Safety Pharmacology, GlaxoSmithKline plc, Collegeville, PA, United States2Division of Pharmacology, National Institute of Health Sciences, Kanagawa, Japan3National Toxicology Program, National Institute of Environmental Health Sciences, Durham, NC, United StatesDrug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dtmax) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects earlier in drug research using simpler, in vitro test systems would be a valuable addition to our strategies for identifying the best possible drug development candidates. Thus, testing platforms with reasonably high throughput, and affordable costs would be helpful for early screening purposes. There may also be utility for testing platforms that provide mechanistic information about how a given drug affects cardiac contractility. Finally, there could be in vitro testing platforms that could ultimately contribute to the regulatory safety package of a new drug. The characteristics needed for a successful cell or tissue-based testing platform for cardiac contractility will be dictated by its intended use. In this article, general considerations are presented with the intent of guiding the development of new testing platforms that will find utility in drug research and development. In the following article (part 2), specific aspects of using human-induced stem cell-derived cardiomyocytes for this purpose are addressed.https://www.frontiersin.org/article/10.3389/fphar.2019.00884/fullcontractilityinotropic statecardiomyocytestem cellsmyocardium
collection DOAJ
language English
format Article
sources DOAJ
author Brian D. Guth
Brian D. Guth
Michael Engwall
Sandy Eldridge
C. Michael Foley
Liang Guo
Gary Gintant
John Koerner
Stanley T. Parish
Jennifer B. Pierson
Alexandre J. S. Ribeiro
Tanja Zabka
Khuram W. Chaudhary
Yasunari Kanda
Brian Berridge
spellingShingle Brian D. Guth
Brian D. Guth
Michael Engwall
Sandy Eldridge
C. Michael Foley
Liang Guo
Gary Gintant
John Koerner
Stanley T. Parish
Jennifer B. Pierson
Alexandre J. S. Ribeiro
Tanja Zabka
Khuram W. Chaudhary
Yasunari Kanda
Brian Berridge
Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms
Frontiers in Pharmacology
contractility
inotropic state
cardiomyocyte
stem cells
myocardium
author_facet Brian D. Guth
Brian D. Guth
Michael Engwall
Sandy Eldridge
C. Michael Foley
Liang Guo
Gary Gintant
John Koerner
Stanley T. Parish
Jennifer B. Pierson
Alexandre J. S. Ribeiro
Tanja Zabka
Khuram W. Chaudhary
Yasunari Kanda
Brian Berridge
author_sort Brian D. Guth
title Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms
title_short Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms
title_full Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms
title_fullStr Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms
title_full_unstemmed Considerations for an In Vitro, Cell-Based Testing Platform for Detection of Adverse Drug-Induced Inotropic Effects in Early Drug Development. Part 1: General Considerations for Development of Novel Testing Platforms
title_sort considerations for an in vitro, cell-based testing platform for detection of adverse drug-induced inotropic effects in early drug development. part 1: general considerations for development of novel testing platforms
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2019-08-01
description Drug-induced effects on cardiac contractility can be assessed through the measurement of the maximal rate of pressure increase in the left ventricle (LVdP/dtmax) in conscious animals, and such studies are often conducted at the late stage of preclinical drug development. Detection of such effects earlier in drug research using simpler, in vitro test systems would be a valuable addition to our strategies for identifying the best possible drug development candidates. Thus, testing platforms with reasonably high throughput, and affordable costs would be helpful for early screening purposes. There may also be utility for testing platforms that provide mechanistic information about how a given drug affects cardiac contractility. Finally, there could be in vitro testing platforms that could ultimately contribute to the regulatory safety package of a new drug. The characteristics needed for a successful cell or tissue-based testing platform for cardiac contractility will be dictated by its intended use. In this article, general considerations are presented with the intent of guiding the development of new testing platforms that will find utility in drug research and development. In the following article (part 2), specific aspects of using human-induced stem cell-derived cardiomyocytes for this purpose are addressed.
topic contractility
inotropic state
cardiomyocyte
stem cells
myocardium
url https://www.frontiersin.org/article/10.3389/fphar.2019.00884/full
work_keys_str_mv AT briandguth considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT briandguth considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT michaelengwall considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT sandyeldridge considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT cmichaelfoley considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT liangguo considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT garygintant considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT johnkoerner considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT stanleytparish considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT jenniferbpierson considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT alexandrejsribeiro considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT tanjazabka considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT khuramwchaudhary considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT yasunarikanda considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
AT brianberridge considerationsforaninvitrocellbasedtestingplatformfordetectionofadversedruginducedinotropiceffectsinearlydrugdevelopmentpart1generalconsiderationsfordevelopmentofnoveltestingplatforms
_version_ 1716797761477672960